Gene · 6900
Papers4,207
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
481 to 500 of 4,207
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
HAS-Flow May Be an Adequate Method for Evaluating Human T-Cell Leukemia Virus Type 1 Infected Cells in Human T-Cell Leukemia Virus Type 1-Positive Rheumatoid Arthritis Patients Receiving Antirheumatic Therapies: A Retrospective Cross-Sectional Observation Study. | Viruses | 2023 | 36851682 | PubTator, text mining | PubMed |
| Tumour‑derived exosomes and their emerging roles in leukaemia (Review). | Exp Ther Med | 2023 | 36845960 | PubTator, text mining | PubMed |
| Tax evasion, psychological egoism, and revenue collection performance: Evidence from Amhara region, Ethiopia. | Front Psychol | 2023 | 36844346 | PubTator, text mining | PubMed |
| A Rare Phenomenon of Isaacs Syndrome: A Case Report. | Cureus | 2023 | 36843819 | PubTator, text mining | PubMed |
| Identification of novel miRNAs potentially involved in the pathogenesis of adult T-cell leukemia/lymphoma using WGCNA followed by RT-qPCR test of hub genes. | Infect Agent Cancer | 2023 | 36841815 | PubTator, text mining | PubMed |
| Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation. | Pharmaceutics | 2023 | 36839768 | PubTator, text mining | PubMed |
| Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool. | Genes (Basel) | 2023 | 36833320 | PubTator, text mining | PubMed |
| Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review. | Biomolecules | 2023 | 36830619 | PubTator, text mining | PubMed |
| Anticancer Drugs Paclitaxel, Carboplatin, Doxorubicin, and Cyclophosphamide Alter the Biophysical Characteristics of Red Blood Cells, In Vitro. | Biology (Basel) | 2023 | 36829507 | PubTator, text mining | PubMed |
| LGI3/2-ADAM23 interactions cluster Kv1 channels in myelinated axons to regulate refractory period. | J Cell Biol | 2023 | 36828548 | PubTator, text mining | PubMed |
| HBZ upregulates myoferlin expression to facilitate HTLV-1 infection. | PLoS Pathog | 2023 | 36827461 | PubTator, text mining | PubMed |
| Insight into Oncogenic Viral Pathways as Drivers of Viral Cancers: Implication for Effective Therapy. | Curr Oncol | 2023 | 36826111 | PubTator, text mining | PubMed |
| The PRMT5 inhibitor EPZ015666 is effective against HTLV-1-transformed T-cell lines in vitro and in vivo. | Front Microbiol | 2023 | 36819050 | PubTator, text mining | PubMed |
| Geographic distribution, clinical epidemiology and genetic diversity of the human oncogenic retrovirus HTLV-1 in Africa, the world's largest endemic area. | Front Immunol | 2023 | 36817417 | PubTator, text mining | PubMed |
| The Alzheimer's disease-linked protease BACE1 modulates neuronal IL-6 signaling through shedding of the receptor gp130. | Mol Neurodegener | 2023 | 36810097 | PubTator, text mining | PubMed |
| STLV-1 Commonly Targets Neurons in the Brain of Asymptomatic Non-Human Primates. | mBio | 2023 | 36802226 | PubTator, text mining | PubMed |
| HTLV-1 persistence and the oncogenesis of adult T-cell leukemia/lymphoma. | Blood | 2023 | 36800643 | PubTator, text mining | PubMed |
| Research progress of PBX1 in developmental and regenerative medicine. | Int J Med Sci | 2023 | 36794159 | PubTator, text mining | PubMed |
| Management equity incentives and corporate tax avoidance: Moderating role of the internal control. | Front Psychol | 2023 | 36794087 | PubTator, text mining | PubMed |
| Pathogenomic Signature and Aberrant Neurogenic Events in Experimental Cerebral Ischemic Stroke: A Neurotranscriptomic-Based Implication for Dementia. | J Alzheimers Dis | 2023 | 36776051 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6900/papers?page=25